In vitro drug response assays showed Bcl-2-negative breast cancers to be more susceptible to chemotherapeutic drugs than bcl-2-positive (Yang et al, 2000), but immunohistochemical studies of breast cancers have been less conclusive (Krajewski et al, 1995). This evidence concerns the gene BCL2 and breast carcinoma.